ABT-299 is a prodrug of a platelet-activating factor (PAF) antagonist that exhibits significant inhibitory activity on PAF-induced β-platelet globulin release in vitro after in vivo administration in humans, an effect that may be partially attributed to the pyridine-N-oxide metabolite.
Products | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Others | Products > Signaling Pathways > Platelet-activating Factor Receptor (PAFR)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.